Ligand Pharmaceuticals

Ligand generates revenue primarily through royalty payments on approved drugs and milestone payments from licensing agreements. It does not manufacture or market drugs itself. The model involves acquiring or co-funding late-stage compounds and then collecting a percentage of future sales (per public financial filings).

Ligand typically targets late-stage clinical and approved assets. It partners with biotech and pharmaceutical companies to fund development in exchange for royalty streams. This is distinct from venture capital, as Ligand focuses on de-risked compounds with clearer regulatory pathways (per the firm's investor presentations).

No, Ligand is a publicly traded company (NASDAQ: LGND) that manages its own balance sheet. It does not raise pooled investor capital like a traditional asset manager or family office. Its funding comes from its own cash flow and debt financing (per SEC filings).

Ligand's portfolio concentrates on biotech and pharmaceuticals, specifically oncology, central nervous system disorders, and infectious diseases. It avoids non-healthcare sectors. The firm also has an animal health division, allowing it to diversify within healthcare (per annual reports).

Ligand partners with major drug developers through license and co-development agreements. For example, it holds a royalty stream on Kyprolis, co-developed by Amgen and licensed from Ligand. These partnerships typically involve upfront payments, milestones, and ongoing royalties (per the firm's historical filings).

No, Ligand is a publicly held corporation, not a family office. It is traded on NASDAQ and subjet to SEC reporting requirements. Its business model — collecting royalties from drug licensing — resembles an asset manager but without external client capital (per corporate governance disclosures).

Ligand mitigates risk by diversifying across dozens of partnered programs and multiple therapeutic areas. It avoids drug-development failure risk by focusing on approved or late-stage assets. Additionally, its contracts include milestone payments that create cash flow before final approval (per investor relations materials).